Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
Eric Jonasch MD
Eric Jonasch MD Advisory Board
See All Experts
Published in Oncology and
1 other channel

News · February 17, 2021

ASCO GU 2021: Talazoparib Demonstrates Durable Antitumor Activity in Metastatic Castration-Resistant Prostate Cancer

Antitumor effects were most notable in patients with BRCA1/2 alterations

PracticeUpdate Editorial Team

 

 Save  Recommend
 Share

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading

Most Read This Week

Recently Updated